Zions Bancorporation N.A. Increases Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Zions Bancorporation N.A. raised its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,514 shares of the company’s stock after purchasing an additional 1,396 shares during the quarter. Zions Bancorporation N.A.’s holdings in Medpace were worth $2,829,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Proficio Capital Partners LLC boosted its position in shares of Medpace by 34,497.4% during the fourth quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company’s stock valued at $80,575,000 after purchasing an additional 241,827 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Medpace during the 4th quarter valued at $78,144,000. Iron Triangle Partners LP purchased a new stake in shares of Medpace in the 3rd quarter worth about $64,371,000. GW&K Investment Management LLC increased its stake in shares of Medpace by 93.9% in the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock worth $91,516,000 after acquiring an additional 133,379 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after acquiring an additional 109,886 shares during the period. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Down 1.8 %

Shares of NASDAQ:MEDP opened at $324.51 on Wednesday. The stock has a market capitalization of $9.89 billion, a PE ratio of 25.69, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. The firm’s 50 day moving average price is $337.16 and its 200-day moving average price is $339.57. Medpace Holdings, Inc. has a twelve month low of $302.01 and a twelve month high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. Analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a report on Monday. Robert W. Baird increased their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Finally, Leerink Partners began coverage on shares of Medpace in a research note on Monday. They set a “market perform” rating and a $330.00 price objective for the company. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Medpace currently has a consensus rating of “Hold” and a consensus price target of $376.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.